Sabrina Nucera

Catania, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Corrigendum to "Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching" [Eur J Cancer 242 (2026) 116818].

Corrigendum to "Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching" [Eur J Cancer 242 (2026) 116818].

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 06, 2026

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Journal: Nature communications

Published: April 15, 2026

Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989].

Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989].

Journal: ESMO open

Published: January 06, 2026

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 18, 2025

Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer.

Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer.

Journal: Critical reviews in oncology/hematology

Published: May 05, 2025

Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis.

Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis.

Journal: JNCI cancer spectrum

Published: April 15, 2025

Correlation between histopathological features and recurrence score according to menopausal status in HR+/HER2- breast cancer patients: a retrospective study.

Correlation between histopathological features and recurrence score according to menopausal status in HR+/HER2- breast cancer patients: a retrospective study.

Journal: Exploration of targeted anti-tumor therapy

Published: January 31, 2025

Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review.

Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review.

Journal: Breast (Edinburgh, Scotland)

Published: November 29, 2024

Corrigendum to "Navigating the complex relationship between human gut microbiota and breast cancer: Physiopathological, prognostic and therapeutic implications" [Cancer Treat. Rev. 130 (2024) 102816].

Corrigendum to "Navigating the complex relationship between human gut microbiota and breast cancer: Physiopathological, prognostic and therapeutic implications" [Cancer Treat. Rev. 130 (2024) 102816].

Journal: Cancer treatment reviews

Published: October 20, 2024

Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis.

Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis.

Journal: Cancer treatment reviews

Published: August 16, 2024

Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study.

Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study.

Journal: ESMO open

Published: July 03, 2024

Navigating the complex relationship between human gut microbiota and breast cancer: Physiopathological, prognostic and therapeutic implications.

Navigating the complex relationship between human gut microbiota and breast cancer: Physiopathological, prognostic and therapeutic implications.

Journal: Cancer treatment reviews

Published: June 16, 2024

Showing 1-12 of 17

Last Updated: 09/26/2026